{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"315.39","value":"49.88"},{"groupId":"OG001","spread":"123.95","value":"17.07"},{"groupId":"OG002","spread":"254.53","value":"6.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"371.92","value":"84.36"},{"groupId":"OG001","spread":"147.16","value":"25.53"},{"groupId":"OG002","spread":"353.06","value":"11.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Cycle 3 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"Serum Concentration Achieved at the End of the Infusion (Ceoinf) refers to the amount of drug present in the blood (serum) immediately after the completion of an infusion. It represents the concentration measured at the exact time the infusion ends, before any significant elimination or distribution occurs.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1/0.3/1/3/10 mg/kg every 2 weeks","id":"OG000","title":"Cohort 1 Uninfected HCC"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3/1/3 mg/kg every 2 weeks","id":"OG001","title":"Cohort 1 HCV Infected"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1/0.3/1/3 mg/kg every 2 weeks","id":"OG002","title":"Cohort 1 HBV Infected"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants in Cohort 1 with baseline and at least 1 post-baseline assessment; uninfected HCC, HCV-infected, and HBV-infected participants reported together as pre-specified.","reportingStatus":"POSTED","timeFrame":"At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)","title":"Serum Concentration Achieved at the End of the Infusion (Ceoinf)","type":"SECONDARY","unitOfMeasure":"ug/mL"}